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Abstract
The present review is aimed at elucidating relatively new aspects of mucoadhesion/mucus
interaction and related phenomena that emerged from a Mucoadhesion workshop held in
Munster on 2-3 September 2015 as a satellite event of the ICCC 13th –EUCHIS 12th. After a
brief outline of the new issues, the focus is on mucus description, purification and mucus/mucin
characterization, all steps that are pivotal to the understanding of mucus related phenomena
and the choice of the correct mucosal model for in vitro and ex-vivo experiments, alternative
bio/mucomimetic materials are also presented. Then a selection of preparative techniques and
testing methods are described (at molecular as well as micro- and macroscale) that may support
the pharmaceutical development of mucus-interactive-systems and assist formulators in the
scale-up and industrialization steps. Recent applications of mucoadhesive systems (including
medical devices) intended for different routes of administration (oral, gastro-intestinal, vaginal,
and nasal) and for the treatment of difficult to treat pathologies or the alleviation of symptoms
are described.
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1. Introduction
The present review stems from a Mucoadhesion workshop held in Munster on 2-3 September
2015 as a satellite event of the ICCC 13th –EUCHIS 12th, held on 30 August- 2 September.
We are perfectly aware that there are a significant number of reviews and papers already
available in the current literature on mucoadhesion and on the relevant pharmaceutical
applications. Thus, in order to avoid duplications, the present review represents an update of
the topic but with special focus on some new aspects of mucoadhesion/mucus interactions,
taking inspiration and advantage of the multidisciplinary nature of the above conference which
gathered bio/medical as well as food technology and physical-chemistry experts.
2. Mucoadhesion
Definition of Mucoadhesion: It is common knowledge that mucoadhesion is a special case of
bioadhesion, which is the ability of a material to adhere to a biological substrate. Thus in
mucoadhesion the biological substrate is represented by mucosal tissue.
Opportunities and applications: The advantages are at least theoretically well understood.
Mucoadhesive formulations are used to temporarily immobilize a delivery device on a specific
site for targeted release and optimal drug delivery due to intimacy and duration of contact.
Indeed it is no news that the short residence times of formulations (due to the various removal
and dilution effects depending on the route of administration) at their intended site of
action/absorption may result in reduced availability to the target tissue. Over the last 30 years,
mucoadhesive polymers and formulations thereof have been developed for buccal, nasal,
ocular, vaginal and oral applications. So far, a considerable number of papers focusing on the
mucoadhesive properties of a wide range of polymeric materials have been published [1-3]. Such
a huge effort has not been paralleled by an increase of clinical applications which are still
limited to a two digit number [4].
Mechanisms: Concerning the mechanisms, it is recognised and experimentally proven that the
interaction between the mucus and mucoadhesive polymers is a result of physical entanglement
and secondary bonding, mainly H-bonding and van der Waals attraction, which according the
many authors, are mainly related to the following polymer properties: capability to create
strong H-bonding, high molecular weight, sufficient chain flexibility, and surface energy
properties favouring spreading onto mucus [5].
Testing methods: It has also to be recognized that a variety of in vitro tests have been developed
by different research groups with the aim of understanding the phenomenon at different length
scales, from observational (tensile testing, flow retention experiments) to molecular, using
sophisticated techniques from fluorescence and confocal microscopy to a variety of
spectroscopic techniques.
The new approaches-innovative aspects: In recent years, other concepts have emerged in the
literature in relation to mucoadhesion. The first observation is that in many physiological
situations the mucus layer is the main actor, and the focus should therefore be on its nature and
complexity/variability depending on the anatomical site and on is sensitivity to various physio-
pathological stimuli. It must also be recognized that mucins and mucus are quite different
substrates and their interactions with mucoadhesives are different and should be taken into
account when dealing with testing methods.
Mucus and food interactions: The comprehension of mucus interactions is also relevant in food
technology for food progression and nutrient digestion and absorption. There is a need to link
the knowledge acquired in this field to the problem of drug delivery.
Mucus penetration and mucoadhesion: Recently the focus has shifted to the mucus penetrating
systems [6, 7] and the study thereof not as an alternative but as a complementary opportunity to
mucoadhesion. They may work together to assure the best results.
Mucomimetic approaches: The recent trend aimed at the development of mucomimetics
substrates to formulate in vitro mucus or mucosae model for both testing and innovative
products should be recognised.
Summary: In line with the ongoing research in the field, the review will illustrate the latest
preparative and testing techniques that may support the pharmaceutical development of
optimized systems, intended for the different routes of administration. This knowledge is the
driving force for the pharmaceutical and related companies in the field. In addition, the review
aims to elucidate the above relatively new aspects of mucus characterization, mucus
penetration and mucomimetic phenomena that represent the basis for a science-based
development of any technological, in vitro, ex–vivo test and for any sustainable formulation
development.
3. Mucus composition and properties as a function of location
Mucus is a highly complex viscoelastic medium that provides a defensive barrier for many
different epithelial surfaces including the respiratory, reproductive and gastrointestinal (GI)
tracts. It performs a range of functions including lubrication, maintenance of a hydrated layer
and it acts as a barrier to pathogens and toxic substances while facilitating the exchange of
gases and nutrients with the underlying epithelium.[8] The mucus layer comprises two different
groups of mucins, secreted and membrane bound.[9] Membrane bound mucins form the
glycocalyx that provides an important link between the cell surface and the secreted gel layer.
On the luminal side of the membrane, these membrane bound mucins have either SEA (self-
cleaving) -domains (MUC1, MUC3, MUC12, MUC13 and MUC17) or von Willebrand
domains (MUC4). The membrane bound mucins play a role in both cellular protection and
signalling [10, 11] through mechanisms such as the regulation of chemokine secretion.
The secreted mucins are produced by submucosal glands and goblet cells and are characterized
by their high molecular weight and high proportion of O-linked carbohydrate.[12] Mucus is
continuously secreted with nearly 10L secreted into the adult GI tract alone.[8] The composition
of mucus varies in different parts of the body. The mucins secreted into saliva are primarily
MUC5B and MUC7 and comprise about 16% of the total protein in saliva [13], whereas the
primary secreted mucin in the stomach is MUC5AC but with lower concentrations of MUC5B
and MUC6. It is possible that small amounts of MUC5B found in the stomach are pulmonary
in origin as pulmonary mucins are expelled via the GI tract. Intestinal secreted mucin is
predominantly MUC2 but again there are low concentrations of MUC6 and MUC11 in the
small intestine and MUC5B, MUC11 and MUC12 in the large intestine. Pulmonary secreted
mucins are primarily MUC5AC and MUC5B [14, 15], both of which are considered to be gel
forming. The secreted mucins of the female reproductive tract are primarily MUC5B but with
lower concentrations of MUC5AC and MUC6.[16] In addition to the mucins the mucus layer
contains lipids, salts, proteins, macromolecules and cellular debris.[17] In particular partially
degraded cellular DNA provides a significant contribution to the viscosity of the mucus layer
[18].
The properties of the various secreted mucins can vary significantly depending on the location
but they are still largely controlled by the basic properties of the mucins. Thus, they are
generally of high molecular weight (in excess of 1MDa) and are primarily hydrophilic. The
extensive glycosylation means that mucins are stiff, extended polymers with a persistence
length of 36 nm [19] and having a negative charge, often associated with sialic acid groups or
sulphate. The properties of mucins in solution very much depends on concentration and what
other components are present in the local environment. The secreted mucins are normally
considered to be gel forming.
In the GI tract the mucus layer varies widely in thickness. It is thickest in the colon and thinnest
in the duodenum [20]. In the intestine the mucus barrier comprises two different regions, known
as tightly adherent and loosely adherent.[21, 22] In the large intestine, these regions are clearly
delineated and under healthy conditions the tightly adherent layer provides a physical barrier
to bacteria. However, in the small intestine this layer is much thinner and the loosely adherent
layer dominates.[23] Measurements of particulate diffusion through human cervical mucus has
shown a network pore size of ~100 nm [24] and AFM images of intestinal mucin have shown a
similar pore size. [25] Despite this data on intestinal mucus, as has already been stated, the small
intestine is dominated by the loosely adherent layer, which is much more heterogeneous. This
layer has been shown to allow the passage of even 2 µm particles provided that they carry a
significant net negative charge. [18, 26] This will be discussed in more detail in Section 9.
4. Preparation of mucin or mucus
a. Purification of secreted mucins
There are very good books that describe the preparation of mucins, especially one edited by
McGuckin and Thornton [27]. As a starting point, we recommend that secreted mucus is
removed by gently scraping the epithelial surface with a plastic scraper and then purified [25].
Because of the large size and complex structure of secreted mucins it is important to use an
extraction buffer containing a strong chaotrope capable of disrupting hydrogen bonding
network. For example, 4M guanadinium hydrochloride has been widely used [28]. The resulting
solution can then be purified using a two-step isopycnic density-gradient centrifugation, in
which the first step removes proteins and the second step nucleic acid. Proceed by adjusting
the sample to a density of 1.4 g/mL with CsCl and centrifuge (55K rpm at 10 °C for 62 h). The
high degree of glycation leaves the mucin strongly Alcian blue positive and this can be used to
identify the mucin containing fractions. Aliquots of fractions can be sampled, absorption at 280
nm measured and 2 μL of each fraction can be spotted and stained with Alcian blue. UV and 
Alcian blue-positive aliquots should then be pooled and diluted in extraction buffer lacking
guanidinium hydrochloride (final guanidinium concentration 0.5 M), adjusted in density to 1.4
g/mL with CsCl, and centrifuged again (50K rpm at 10 °C for 96 h). Again aliquots can be
sampled, measured at 280 nm and stained with Alcian blue. The fraction at 1.4−1.55 g/mL and 
strongly Alcian blue-positive but with weak absorption at 280 nm is identified as the mucin
fraction. More detailed methods for the purification of specific mucins can be gathered from
the literature. For example, MUC5B [29] and MUC7 [30] from saliva, MUC5B from respiratory-
and cervical-tract secretions[31] and MUC2 from intestinal mucus [25]. Confirmation of the
presence of mucin resulting from the purification should be undertaken using
immunoreactions. There is now wide range of antibodies available against mucins from a range
of animal sources indeed for many mucins it is possible to target specific regions of the
molecule.
Although the extraction and purification of mucins are well established methods, some
disadvantages related to the short conservation time, lower yield of production and batch-to-
batch variability lead frequently to the alternative use of commercial mucin. Commercial mucin
the type from Sigma (Germany) or Orthana (Denmark) are purchased in lyophilized powder
which then can be hydrated in ultrapure water or buffers for 3h at room temperature under
gentle stirring. An extensive dialysis allows removals of small ions or low-molecular-weight
additive. Several treatments have been reported in the literature. Rossi et al. increased the
solubility of mucin from Sigma by adding 2% (w/w) SDS to 12% w/w mucins dispersion [32].
SDS was then removed by 2 days dialysis against 10 volumes of 1M urea-1M NaCl, followed
by other 2 days dialysis against 40 volumes water and finally against 0.1 M acetate buffer pH
4.5. Alternatively, the mucin dispersion can be centrifuged for 1 h at 25,000xg, the supernatant
fraction collected, lyophilized and stored at 4°C until usage. The glycoprotein concentration
can be measured by colorimetric method or absorbance reading at 280 nm and calculated on
the basis of the difference before and after the treatment. Samples from Orthana have been
characterized in terms of monosaccharides composition revealing a predominant presence of
neutral O-linked oligosaccharides which confer high hydrophilicity and high solubility up to
200 mg/mL. Solution of this commercial mucin can be prepared by dispersion in water,
extensive dialysis and finally lyophilized. Orthana as well Sigma mucins do not show the
gelling properties upon lowering pH however rheological studies demonstrated the existence
of a concentration-dependent variation of the viscosity from dilute to semi diluted to entangled
state [33].
In addition to preparative methods such as those mentioned above, analytical methods such as
agarose gel electrophoresis can also be used and separation monitored by lectin,
immunochemical or histochemical staining. This method can be used to analyse minimally
treated samples as long as they are protected from degradation. As the separation is based on
the inherent charge of the mucin, it can be used to separate different mucins [34] or different
glycated forms of the same mucin. [35]
b. Biomimetic approaches
In parallel with biological mucin and mucus, efforts to develop artificial mucus or mucus
models have been put forth for long. Easily accessible mucus models or mimics are beneficial
for all research disciplines requiring mucin, mucus or mucosa for a number of obvious reasons;
biological mucus could be difficult to be accessed by some research groups, generally
cumbersome to prepare, and presents ethical issue.[36] Technically, biological mucus samples
may reveal inconsistent structure and properties across studies due to differences between
individual animal sources and/or preparation details. While some mucus models have been
devised clearly in the context of mucoadhesion and drug delivery, some others have been
developed for other purposes and thus may be considered for future mucoadhesion studies.
Growing interests in mucus models are reflected in a few excellent review papers on this
subject published in recent a couple of years, including by Groo and Lagrace[37] and
Authimoolam and Dziubla[38] with a focus on artificial mucus, and by Cook and
Khutoryanskiy[36] with a focus on artificial mucosa, respectively. Briefly, mucus models can
be classified into glycan micro-arrays,[39-42] mucin layers,[43-47] complexes of mucins with
synthetic polymers,[48-52] and synthetic polymers,[53-56] roughly according to the scale. Glycan
micro-arrays have gained popularity for its specificity in probing glycan-binding receptors,
antibodies, and enzymes,[39, 40] and can be applicable to mucoadhesion too. Despite that micro-
arrays with mucin-specific glycan arrays are also readily available,[41, 42] application in the
context of mucoadhesion is rare probably due to the lack of three dimensional, mechanical
barrier character in those systems. In fact, this is a common problem for all other types of two
dimensional mucus models, such as various monolayers of mucins on substrates.[43-47] Mucin-
synthetic polymers complexes were motivated from that self-aggregated mucins, especially
commercially available ones, in aqueous solvent even at physiological concentration or higher
do not reproduce viscoelasticity comparable to that of native mucus.[57] Thus, synthetic
polymers, especially mucoadhesive polymers, are employed as crosslinker to enhance the
network forming capabilities of mucin aggregates. Representative polymers include guar
gum/borate,[50] alginate,[48] poly(acrylic acid),[49] and glutaraldehyde.[52] Some hydrophilic and
network-forming synthetic polymers, such as locust bean gum/tetraborate,[53] poly(acrylic
acid)/(hydroxypropyl)methyl cellulose,[56] poly(styrene) sulfonate,[55] and poly(ethylene
glycol)-block-poly(lactic acid),[54] have been employed even without involving mucin
molecules. The assessment of synthetic polymeric systems or complexes of mucin and
synthetic polymers as mucus models has typically been conducted via characterization of
rheological properties[48-53] and adhesive properties (detachment forces) against mucoadhesive
drug tablets,[56] often in comparison with biological mucus. These two properties represent
mechanical integrity of mucus model and their interfacial chemical properties against
mucoadhesive polymers, respectively, in the context of drug delivery researches. Nevertheless,
no mucus model or mimic that can universally replace biological mucus has emerged yet,
presumably because of diverse and complex properties required for mucoadhesion researches.
5. Preparation of electrospun mucoadhesive formulations
During the last two decades, electrospinning has gained increasing interest as a promising
technique for biomedical applications.[58-60] In drug delivery, nanofibers are appealing due to
their high encapsulation efficiency and flexible encapsulation capacity.[61] Moreover,
electrospun fibers allow for numerous delivery and encapsulation options; blend, core-shell,
particles combined with fibers, etc[62, 63]. Electrospun fibers have a large surface area that allows
for extensive interactions with the surrounding environment, which, depending on the
application, can be mucus or other biological components. Surprisingly, mucoadhesion of
nanofibers has not yet been extensively addressed. From the limited studies (examples from
the literature can be found in Table 5.1), it is evident that the mucoadhesive properties of
nanofibers can be manipulated by changing nanofiber properties, such as the extent of cross-
linking.[64-66] Moreover, the inherent mucoadhesive properties of some biopolymers can be
exploited when developing mucoadhesive nanofibers. Thus, biopolymers with known adhesive
properties (such as alginate and chitosan) have been electrospun with increased bioadhesion of
the nanofibers compared to those made from synthetic polymers.[67, 68] However, the physico-
chemical properties of nanofibers does not necessarily correlate with those of the unprocessed
material,[69] for which reason mucoadhesion of biopolymeric nanofibers in general must be
studied. Also, the effect of fiber morphology on the mucoadhesive properties, such as fiber
diameter, is yet to be explored.
The oral mucosa is permeable and vascularized, and therefore an appealing delivery.[70] The
group of Yang developed a delivery system for the oral mucosa, based on a semi-
interpenetrating network (sIPN) made from gelatin.[71, 72] By cross-linking the fibers using
polyethylene glycol diacrylate (PEG-DA) the authors obtained stable, mucoadhesive fibers.
The mucoadhesion was affected by several factors: stability, porosity, swelling, and PEG
composition of the scaffold.[71] The sIPNs were used as a delivery system for insulin, and the
authors found that the transbuccal permeability of the released insulin was larger than that of
free insulin.[71] Another delivery system targeting the oral cavity was developed by
Tonglairoum et al., who developed polyvinylpyrrolidone/cyclodextrin/clotrimazole sandwich
patches coated with chitosan (CS) or thiolated chitosan (CS-SH) for oral candidiasis.[73] The
authors studied the fiber’s mucoadhesion, and thus the ability to adhere to the oral mucus. It
was shown that fibers coated with CS-SH exhibited a higher mucoadhesive strength compared
to CS coated, which is in line with thiolated chitosan providing stronger interaction with the
mucus.[73] The mucoadhesive properties of nanofibers can also be controlled by adding
mucoadhesive small molecules. For instance, Wongsasulak et al. obtained increased
mucoadhesion of zein–chitosan composite electrospun fibers by addition of alpha-tocopherol
(a-TOC).[65, 74] Electrospun nanofibers have also been studied for vaginal drug delivery.[75, 76]
In a study by Zong et al., polyethylene oxide (PEO)/polylactide composite electrospun
nanofibers was developed and loaded with cisplatin for local chemotherapy. The mucoadhesive
properties of the nanofibers caused the fibers to stay in the vagina and release the drug, whereas
the gel leaked out. Accordingly, the nanofibers facilitated increased bioavailability of the drug
as compared to a gel.[75] Electrospun fibers have shown promising results for mucosal drug
delivery, however the full potential is still to be revealed.
Table 5.1 Examples of electrospun formulations for drug delivery.
Mucosal target Fiber material Drug Ref
Buccal mucosa
chitosan or thiolated chitosan/polyvinyl
alcohol
Garcinia mangostana
extract
[77]
Buccal mucosa polyvinyl alcohol Di- phenhydramine [66]
Buccal mucosa polyvinyl alcohol Docetaxel [78]
Buccal mucosa
Gelatin and photo-reactive polyethylene
glycol diacrylate
Nystatin, insulin [71, 72]
Buccal mucosa chitosan/polyvinyl alcohol Clotrimazole [79]
Buccal mucosa
polyvinylpyrrolidone/cyclodextrin/clotri
mazole and chitosan/polyvinyl alcohol
Clotrimazole [73]
Sublingual
mucosa
polyvinyl alcohol and sodium
alginate/polyvinyl alcohol
Insulin
[64]
GI mucosa polycaprolactone Diclofenec sodium [80]
Gastric mucosa Zein, chitosan and poly(ethylene oxide) α-tocopherol [65, 74]
Vaginal mucosa
polystyrene coated with poly(allylamine
hydrochloride) or dextran sulfate sodium
HIV entrapment [81]
Vaginal mucosa cellulose acetate phthalate TMC 125/Viread [76]
Vaginal mucosa poly(ethylene oxide)/polylactide Cisplatin [75]
Ocular mucosa Polyvinyl alcohol/polycaprolactone
Timolol maleate and
dorzolamide
hydrochloride
[82]
6. Methods for molecular scale testing of mucoadhesion
a. Spectroscopic studies
Over the last 20 years a range of spectroscopic methods have been used for the in vitro analysis
of the mucoadhesive behaviour of polymeric materials, and the determination of their affinity
toward mucin at the molecular level.[83-85] In particular, the interactions between
glycoproteins\mucins with mucoadhesive polymers have been investigated by 1H and/or 13C
Nuclear Magnetic Resonance (NMR) spectroscopy or by NMR diffusion measurements.
Analysis using NMR is advantageous, as no sample derivatization or pre-treatment is needed
and due to the advantage of non-alteration of the normal bio-functionality of the biomolecules.
Uccello-Barretta and co-workers have used proton selective relaxation rate NMR
measurements for the determination of mucoadhesive properties of different
polysaccharides.[86] Mucoadhesivity can be determined by exploiting the possibility to detect
changes of affinity to mucin of small probe molecules due to the mucin–polysaccharide
interactions. They have demonstrated the affinity of ketotifen fumarate (KT) to mucin, and they
have used KT as an interaction probe to compare the bovine submaxillary mucin affinities of
tamarind-seed polysaccharide and larch arabinogalactan.[87] Diclofenac sodium salt has also
high affinity for mucin (and low affinity for the polysaccharides), and was also employed as
mucoadhesivity probe for polysaccharide mixtures containing tamarind seed polysaccharide
and hyaluronic acid.[88] It has been shown that the selective relaxation rate of the ligand is a
more sensitive indicator of binding than the non-selective relaxation rate is. Earlier studies
using 1H and 13C Nuclear Magnetic Resonance, indorsed that the hydrogen bonds formed
between the carboxylic acid of poly(acrylic acid) and the glycoprotein component of mucus,
play a significant role in the process of mucoadhesion.[89, 90] Moreover, Griffiths et al., has used
pulsed-gradient spin-echo (PGSE-NMR) diffusion measurements to study the interactions of
various model polymer therapeutics with mucin and to quantify their diffusion within mucin
solutions.[91] A strong interaction with mucin was observed for a series of polyamidoamine
dendrimers and hyperbranched poly(ethylene imine), which displayed a characteristic pH-
dependent profile and led to significant reductions in their rates of diffusion.
The use of attenuated total reflectance-fourier transform infra-red spectral analysis (ATR-
FTIR) is another spectroscopy method to study the interfacial interaction/absorption, and the
diffuse phase across the interface of mucoadhesive polymers and mucins segments.[92]
Sriamornsak et al., studied the mechanisms of gastrointestinal mucoadhesion of different
pectin films in contact with mucin in different media.[93] The diffusion of water was used as an
indirect measurement of any change resulting from the interpenetration of polymer–mucin
chains at the aqueous solution-polymer film interface.[94] The ATR-FTIR data confirmed the
formation of hydrogen bonds and the changes resulting from the interpenetration of pectin–
mucin chains at the film interface. Furthermore, by using ATR–FTIR spectroscopy Xiang and
Li suggested that intra-polymer interactions, and inter-surface interactions played opposite
roles in the mucoadhesion performance of cationic polymers, at the negatively charged buccal
mucosa surface.[95] The intra-polymer interactions can increase the crosslinking within the
polymer and lead to the decrease of mucoadhesion, while the inter-surface interactions can
promote mucoadhesion of the polymer. Optimal mucoadhesion can be achieved by balancing
these two interactions. In a recent study, ATR-FTIR was used to investigate the molecular
interactions between a chitosan hydrogel (consisting of non-ionic surfactant vesicles,
niosomes, with chlorotoxin) and various cell lines for cancer therapy. The specific
accumulation of mucoadhesive chitosan on the surface of ovarian epithelial carcinoma cells
was confirmed, demonstrating chitosanʽs specificity in targeting of mucin antigen 
overexpressing tumor cells.[96]
Several of the mucoadhesive studies focus on bulk polymers, however, interest in the
mucoadhesion at the nanoscale has been growing the last years.[97, 98] In fact, the mucoadhesion
ability of nanoparticulate systems to mucin is affected by their surface properties (hydrophobic,
hydrophilic), surface charges and their size. To detect the mucoadhesive phenomena in the
intestinal tract after oral administration of nanoparticulate systems, confocal laser scanning
microscopy (CLSM) has been used.[99, 100] Chen et al., investigated the adhesion of chitosan-
modified liposomes, (average diameter of ~200 nm) using CLSM and fluorophotometry with
coumarin 6 as the fluorescent probe.[101] Their studies indicated that the positively charged
surface charge of the liposome particles played an important role in their interaction with the
negatively charged mucin fibres. In another study, the in vivo mucoadhesion of pH-responsive
thiolated chitosan nanoparticles for oral low-molecular weight heparin delivery was assessed
using CLSM.[102] Fluorescein-5-isothiocyanate (FITC)-labelled nanoparticles were prepared
and the intensity of green fluorescence in the small intestine epithelium of rats after oral
administration were evaluated. It is to note, that the CLSM method is sensitive to detect the
organic dye-labelled association of nanoparticles to the mucosal layer of the animal intestine,
and does not modify the properties of the developed formulations of the nanoparticles. Instead
of organic fluorescence materials, orally administered quantum dots (QDs, semiconductor
nanocrystals with diameters of 1–10 nm), could be used as fluorescence markers. Tahara and
co-workers have developed QD-loaded liposomes which had high biocompatibility and low
toxicity in Caco-2 cells.[103] By using CLSM, the fluorescent signal of QDs in the liposomes
could be detected in the intestinal mucosa after oral administration. Thus, QDs can be used for
tracing and detecting bioadhesion and uptake of liposomes in in vivo applications. The
relaxation NMR approach, using dexamethasone 21-phosphate as a mucoadhesivity probe,
confirmed the in vitro mucoadhesivity of nanoparticles obtained from quaternary ammonium
chitosan conjugates.[104] The high surface area of nanoparticulate aggregates is remarkably
enhancing the interactions with bovine submaxillary mucin. In addition to nanoparticles and
liposomes, block polymeric micelles were also tested for the development of mucoadhesive
drug loaded nanovehicles. The mucoadhesivity of solutions of micelles having acrylated end
groups was characterized by using 1H NMR.[105] To quantify the extent of reaction, the
decreased area under the curve in the vinyl proton regime of the NMR spectra, (indicating
interactions between the acrylates and thiols present in cysteine residues of the mucin), was
evaluated.
Overall, spectroscopic studies are very useful to investigate the interactions between polymers
or nanoparticulate systems with mucus. The choice of the mucoadhesion spectroscopy method
affects the characterization of their bioadhesive\diffusion properties and the determination of
the mucoadhesive strength.
b. Atomic Force Microscopy
Atomic force microscopy (AFM) is another method that has been used in mucoadhesion
measurements. The imaging mode can provide essential information about the amount and
conformation of material adhering to the sample, while force spectroscopy enables sensitive
adhesion measurements. In order to increase the surface contact area between the tip and the
sample in force measurements, it is advantageous to prepare a so-called ‘colloidal probe’. As
shown in Figure 6.1, a colloidal-sized particle is attached to the AFM cantilever using two
component epoxy glue. The colloidal probe and the sample surface can be further
functionalized with molecules of interest (mucin, APTES, -COOH, -NH3, -OH groups,
antibodies and others). Later on, the cantilever is moved towards the surface in the vertical
direction. The deflection of the cantilever is measured during the approach and retracts of the
probe; as a result, a force-distance profile is obtained. The maximum force of adhesion (Fadh)
and the work of adhesion (Wadh) can be determined from the retract curve.
Figure 6.1 Scheme of experimental setup and force-distance profile for mucoadhesion measurements.
The colloidal probe approach has been used by Cleary et al. in order to measure the adhesion
between a Pluronic-PAA modified glass bead and the mucous substrate [43]. The mucoadhesion
was studied in conditions of varying pH and ionic strength. It was also found that the time of
contact between the probe and the sample affects the adhesive forces. Prolonged contact favors
interdiffusion and interpenetration of polymer chains and mucin network, resulting in increased
adhesive force. Pettersson and Dedinaite investigated the interactions between mica surface
and silica particles coated with mucin and mucin-chitosan layers [106]. In order to mimic the
daily oral care procedure and its influence on mucous layers, the films were exposed to the
anionic surfactant SDS. Another interesting approach to the colloidal probe method was
presented by Iijima et al., who have measured the interactions between mucin layers and
stimuli-responsive drug delivery vehicles [45]. Instead of using the colloidal sized, glass or silica
particle attached to the AFM cantilever, the nanogel particles were freeze-dried and the
resulting granules were directly adhered to the tip by means of micromanipulation system.
Joergensen et al. used the image analysis of AFM scans in order to evaluate the mucoadhesive
properties of different pectins [107]. Mucin coated mica was scanned in AFM liquid cell before
and after incubation with polymer solution, followed by comparison of the roughness
parameters extracted from the images. Sriamornsak et al. investigated the structures of mucin,
pectin and their mixtures in acidic medium and deionized water, observing formation of large
aggregates in neutral pH conditions [47]. Similar study by Deacon et al. assessed the interactions
between pig gastric mucin and chitosan [108].
AFM in mucoadhesion measurements presents both advantages and limitations. It allows
sensitive force measurements as a function of pH, ionic strength or time of contact, but it is
also time-consuming and can be affected by a choice of place in the case of heterogeneous
samples.
c. Scattering techniques (SAXS, SANS, SLS and DLS)
The detailed macromolecular structure of mucin has been addressed at molecular level using
high-resolution scattering techniques, namely, synchrotron SAXS [109-111], SANS [110, 112] and
static and dynamic light scattering [33]. This has allowed accounting for the properties of mucin
samples of different biological origin and methods of preparation. Thus, the cylindrical model,
and more recently, the double-globular (or “dumbbell”) comb model, has been used to describe
the complex mucin structure [33, 109, 112]. The schematic structure of mucin at different length
scales and its mechanical response at varying pH are represented in Figure 6.2.
Figure 6.2. Schematic representation of the biochemical structure of gel-forming mucin at
different magnifications: A) entangled mucin network; B) mucin monomers cross-linked
through disulfide bonds ; C) mucin monomer with globular naked-protein regions and D) low
scale representation of the bottle-brush highly glycosylated region of mucin (Sources: Modified
from [8, 113]; mechanical spectra of pig’s gastric mucin (PGM) as a function of pH taken from
Celli et al. [114]; double-globular comb structural parameters taken from Di Cola et al. [109] and
corresponding to pharmaceutical mucin sample “Orthana” in aqueous medium in absence of
salt). With permission of American Chemical Society and Elsevier.
Table S1 summarizes the results of biophysical studies, based on scattering techniques, namely,
synchrotron SAXS, SANS, and SLS and DLS, that have addressed the structural properties of
purified mucins of different biological origin. Fundamental parameters probed include the
radius of gyration (Rg), the coil overlap concentration (c*) and the slope of the intensity
scattering curves (also known as the fractal dimension (df)). These parameters have been
determined at varying conditions of pH, solvent, concentration and temperature. The wealth of
documented studies has contributed to the elucidation of the mechanisms and molecular events
that govern the properties of mucin which underlie its biological functions such as the
formation of gel networks. Indeed, mucin participates in the formation of the gel which
prevents the digestion of stomach epithelia caused by the acidic gastric juice. This is a function
of pH, but also mucin concentration and ionic strength. At physiological conditions, the high
concentration of mucin (> 20 mg/mL) and the high-molecular-weight of the molecules, favor
the formation and stabilization of an entangled network which behaves as a weak reversible
gel [115]. On the other hand, mucin undergoes to sol-gel transition [114, 116] a low pH (pH < 4)
due to a conformational change in which hydrophobic domains of the non-glycosylated
cysteine-rich regions become exposed and the negative charges of the sugars residues
responsible of maintaining the expanded structure get protonated. As observed in vitro for
native mucin, this phenomenon is accompanied by increase of the size at pH ~2 [117, 118] due to
aggregation of mucin by a combination of hydrophobic and electrostatic interaction and
entanglement of the sugar chains resulting in an increase of the viscosity of the solutions [114,
119]. In support of the model proposed for mucin gelation, AFM images have shown that mucin
is in an extended fiber-like shape at pH 6.0, whereas it forms well-defined clusters at pH 2.0
[117]. Consequently, the different conformation of mucin throughout the mucus layer allows
selective diffusion of HCl. At low concentration [116], in presence of high ionic strength [119],
commercial mucin [57], does not gel. However, pH-dependent interactions, as shown by DLS
and CD-spectroscopy, are attributed to a conformational transition of mucin at pH < 4.0 [120,
121] that imparts some fluidic viscoelasticity to the bulk sample [114].
Recent studies using synchrotron SAXS have aimed to gain insight into the interaction between
soluble commercial pig gastric mucin and alginates of high-molecular-weight (~ 400 kDa) and
low-molecular-weight (~4 kDa) [122]. Firstly, the structure of mucin alone (at 3 mg/mL), at three
different values of pH, namely at 1.2, 2.5 and 4.0, was investigated. The scattering curves were
characterized by a single fractal dimension, df = -1.6 at pH 4.0, which at low-q range, increased
to df = -2.6 when lower pH were assessed. This observation is consistent with a pH-driven
conformational transition in the mucin, in agreement with observations in other mucin samples
differing in origin and preparation methods, as revealed from other techniques. The structure
of mucin in three different concentration (namely, at 0.3, 1.5 and 3.0 mg/mL) was characterized
by different scattering profile, being the one at lower concentration ideal to calculate the radius
of gyration (Rg) that afforded a value of ~18 nm. Interestingly, when the more diluted mucin
was mixed with two different types of alginates, different effects in the high-q range of the
intensity scattering plot were observed. Indeed, the addition of the low-molecular-weight
alginate produced a scattering profile in which the high-q range resembled the one of mucin at
high concentration (3 mg/mL). By contrast, this effect was less pronounced when adding the
high-molecular-weight alginate, where the high-q region resembled more closely the behavior
of mucin at low concentration. Based on this evidence, along with that from fluorescence
quenching spectroscopy, viscosimetry and DLS studies, a general model was proposed to
explain the interaction of soluble mucin with polyanions. This model accounts for the influence
of molecular weight, charge and degree of chain contraction (Figure 6.3). Although the overall
net charge of mucin is negative, positively charged patches are expected to occur in the non-
glycosylated protein globular regions of mucin due to the presence of histidine, arginine and
lysine. These positive patches represent sites for the interaction with negatively charged
polysaccharides.
Figure 6.3 Model of interaction between the mucin in its double-globular comb mucin
structure and alginate as a function of alginate´s Mw (Alg 4 = 4 kDa; and Alg400 = 400 kDa)
and chain flexibility [122]. With permission of American Chemical Society.
Low-molecular-weight and stiff polyanions will interact mainly with the sites available on the
globular regions without influencing the preferred conformation of mucin. Thus, minimal
variation of the bulk properties such as size and viscosity are expected to occur. However, due
to the small size, low-molecular-weight polyanions are able to penetrate in the globular
structure inducing eventually rearrangement of the protein. On the other hand, high-molecular-
weight and more flexible polyanions, due to the large size, might act as bridges between distant
available sites thus influencing the initial conformation of mucin and favoring a reduction of
the overall hydrodynamic volume.
7. Methods for macroscale testing of mucoadhesion
The methods to study mucoadhesion can be classified depending on the underlying physical
phenomena involved and also depending on the type of formulation that can be tested. Table
7.1 and Table S2 summarize the investigative techniques available. In this Section, we focus
on those that probe macroscale phenomena.
Table 7.1. In vitro methods used to study mucoadhesion as classified on the basis of the
physical phenomena involved.
Test method Formulation
Mucosal surface/mucosa
mimetic material/mucin
Methods based on the mechanical force determination [123]
Texture Analyzer
Compressed polymers tablets
[56]; Polymers solutions [124];
Casted polymer films [125, 126];
Polymer gels [127-129];
Compacted polymer
microparticles into tablet [130]
Animal mucosal tissue [126,
128, 130]; Mucosa-mimetic
hydrogels [56]; Mucin-coated
(Sigma) filter papers [124,
125]; Mucin (Sigma) disc
[127]; PGM (Sigma) gels [129]
Modified balance/modified
surface tensiometer
Polymer coated glass [131];
Compressed polymer [132, 133];
Polymer cups [134]
Animal mucosal tissue [132-
135];
Tensile tester
Polymer paste [136]; Hydrogels
[137]
Plexiglas® disk [136]; gelled
BSM [137]
Tensile stress tester Composite hydrocolloids [138] Filter paper [138]
Rotational cylinder
Compressed polymer tablets [1,
133]
Animal mucosal tissue [1,
133]
Atomic Force Microscopy
(AFM)
Polymer coated glass
microsphere [43]; Polymer
solution [139]; Mucin-polymer
complexes [47, 108]
Human buccal cells [139];
Freshly purified PGM [108];
PGM (Sigma) [47]
Methods based on mucoadhesive interaction
Surface Plasmon
Resonance (BIACORE®)
Covalently-bound polymer
on CM5 chip [140]
Submicron-sized commercial
PGM suspension [140]
Dynamic light scattering
(DLS)
Mucin-polymer complexes
[121, 141]
Turbidity
Mucin-polymer complexes
[121, 142]
IR-NMR
Freeze-dried mucin-polymer
mixed solutions [143]
Crude homogenized porcine
gastric mucus [143]; PGM
solution [143]:
Analytical ultracentrifuge
Polymer-mucin mixed
solutions [144-146]
PGM from different gastric
regions [144]; HGM [145]
Impedance crystal quartz
microbalance (QCM)
Polymer solutions; Polymer-
micelles [147]
BSM (Sigma) solution [147]
Method based on flow forces
Flow through systems
Fluorescent labeled
nanoparticles [148, 149];
Polymer microparticles [150]
Ocular tissue [148]; PGM
(Sigma) solution [149]; Isolated
small rat intestine [150];
Method based on fluorescent probes
Fluorescence
determination
Fluorescent labeled-
nanoparticles [151];
Fluorescent labeled-polymer
solutions [152, 153]; Polymer
solutions [154]
Animal mucosal tissue [151-153]
Pyrene-labeled human
conjunctival epithelial cells
[154]
Multiple Particle Tracking Fluorescent particles [155] Purified PGM hydrogels [155]
Method based on rheological solution properties
Viscometer
Polymer-mucin mixed
solution [122, 142, 156, 157]
Mucin (Sigma) solutions [122,
124, 142, 157-159]; Homogenised
porcine gastric mucus [160, 161]Rheometer
Polymer-mucin mixed
solution [124, 141, 142, 158, 159]
a. Rheology including polymer interaction in dilute solution
The interaction occurring between mucus and mucoadhesive polymers in mixed systems
produces variation in the flow properties of the mixtures respect the ones of the single
components. Thus, the study of the rheological properties of mixtures of mucus or mucin in
solution with mucoadhesive polymers has been widely exploited. Steady-shear measurements
of viscosity,  (defined as the resistance of a fluid to the imposed shearing force), and
oscillatory shear determinations of the mechanical viscoelastic moduli (namely, storage and
loss moduli, G’ and Gʺ, respectively), have been used to study liquid and gel-like systems,
respectively [162]. In general, when two different macromolecular species (e.g., polysaccharide
and protein) are mixed in solution, either attractive or repulsive interactions can take place [163]
(Figure 7.1). Attractive interactions can result in the formation of a complex that either remains
as a soluble colloidal complex or else precipitates as a coacervate. Repulsive interactions in
turn, depending on the concentration of the macromolecular species, can lead to phase
separation or co-solubility [163]. In the case of associative interactions, the bulk viscosity of
dilute mixed solutions is expected to decrease due to overall reduction of the hydrodynamic
volume of the macromolecules when they are combined. However, in some other cases,
cooperative intra and inter-polymer interaction can induce increase in viscosity which is higher
than the expected sum of the individual contribution, up to physical gelation. This “synergistic”
interaction was previously observed in xanthan and galactomannan or in plasma proteins and
egg albumin mixed system [162, 164]. In repulsive interactions, the viscosity of mixed solutions
is expected to remain similar to those of the individual stocks. However, if the conformation
of one of the molecules changes due to the exclusion into a segregated phase, then the viscosity
of the mixture can also deviate from the expected additive line. Viscosity synergism cannot
distinguish between binding interaction and exclusion effects [165], unless experimental criteria
are applied. In the experimental conditions in which polysaccharides and mucin solutions are
in the dilute regime (rel ~2; sp ~ 1), polymer exclusion effects are assumed to be negligible
[162] being the polymers well below the overlap coil concentration.
Figure 7.1 Schematic representation of the type of interaction that can occur in protein-
polysaccharides blends in dilute solution mixtures (modified from [163]).
Mucus is a weak viscoelastic gel biological material which possesses both flow (viscosity) and
deformation (elasticity) properties [113]. Such properties are regulated for example during
peristaltic movement or copulation [8]. At higher concentration mucus is characterized by a
shear thinning behavior (i.e. decrease in viscosity upon increase of the shear rate) typical of an
entangled network. However, the soluble fraction of PGM (Sigma) at concentration of ~ 8
mg/mL (in 0.1 M TRIS pH 7.4) was found to behave as Newtonian fluid since any shear-
dependence of the viscosity was observed [157]. The addition of human albumin produces an
increase in viscosity due to association of albumin and mucin [157]. In the context of mucin and
polymer interactions, a rheological approach to screen the mucoadhesive properties of polymer
was described by Hassan and Gallo [156]. The mucoadhesion strength of several polysaccharides
was evaluated by studying the viscosity enhancement occurring upon mixing solution of
polymers with commercial mucin sample using a viscosimeter Brookfield Model RTV
(Brookfield Engineering Laboratories, Stoughton, MD). The increase in viscosity (positive
synergism) respect to the sum of the individual viscosities of the two components measured in
the same conditions as the mixture (in terms of concentration, temperature, time and rate of
shear) but with an Ostwald capillary viscosimeter (Fisher Scientific Co., Pittsburgh, PA) was
attributed to physical entanglement between the two species and defined as component of
bioadhesion (b). For each polymer-mucin system, b was calculated with the following
equation:
b t = - m - p Eq. 1
where  is the measured viscosity of the mixture and p and m the individual viscosity of the
polymer and mucin, respectively.
The b values were found to be inverse proportional to the rate of shear per second (), thus,
the force of bioadhesion F, defined as intermolecular friction force per area unit was calculated
using the equation:
F = b × ߛሶ Eq. 2
Based on this pioneering protocol, several subsequent studies aimed to test the mucoadhesion
of polymers. This procedure could distinguish between positive synergism (interaction), lack
of synergism (no-interaction) or negative synergism of the viscosity or of the mechanical
properties. Mortazavi et al., [166] reported the gel strengthening effect of poly-acrylic acid on
homogenized mucus and observed that was characterized by increased values of G’ (which
reflects the ability of a viscoelastic material to store the elastic energy and recover its initial
shape) and decrease in Gʺ (which reflects the loss of energy as liquid-like flow). Madsen et al.,
[160] described the effect of mucoadhesive type and concentration on the profiles of the
mechanical spectra of the mixtures in order to determine the type of gel formed. Some of the
most relevant works based on rheological methods that have contributed to a systematic
description of the mucoadhesive properties of polysaccharides are summarized in Tables S2
and S3. Sometimes, different outcomes have been observed for the same polymer-mucin
mixture, such as in the case of chitosan-mucin [142, 156] or cellulose derivative-mucin [159, 160]
depending on different experimental conditions, particularly the polymer concentration [158] or
mucin source, making direct comparisons and interpretations challenging [167].
Recent evidence [168], has shown that mixing two stock solutions of chitosan and mucin of
matched rel ~ 2.0, at increasing f ratio (mass proportion of mucin respect the total mass in the
mixture) a reduction in rel to a minimum value (fηmin) occurs beyond which, upon a subsequent
increase in f, the rel increases again to approach that of mucin stock solution. Such behavior
describes a skewed U-shaped curve both in water and 0.1M NaCl (pH 4.5) as shown in Figure
7.2a and b, respectively, for a representative CS-mucin systems. This approach enables to
determine, in a quantitative manner, the degree of interaction, given by the value of the area
under the curve of the relative deviation from the theoretical additive line (or line of “no
interaction”). Also, the method enables to determine the maximum stoichiometry of the
interaction given by the f ratio of minimum rel (fηmin).
Mechanical force studies or rheological synergism are diagnostic of mucus (or mucin)-polymer
interactions, however, no detailed information regarding the underlying molecular mechanisms
of interaction can be deduced from these techniques. Table S3 offers a summary of the major
rheological methods that have been used to study the interactions of polymers and proteins
with mucin solutions and mucus gels.
Figure 7.2 Relative viscosity (ηrel) of chitosan–mucin mixtures of varying compositions
expressed as the mass fraction of mucin (f) respect the total mass in a)water and b)0.1M NaCl
(37°C, pH 4.5, inclination angle 50°). The red dotted line in a) and b) represents the calculated
values of ηrel of the mixtures assuming there is no interaction (additive line). The ηrel values at
f = 0 and 1 are the relative viscosities of the chitosan and mucin stock solutions, respectively.
The lower panels show the normalized data expressed as percentage deviation from the additive
line in c) water and d) 0.1 M NaCl, both at pH 4.5 (mean values ± minimum and maximum,
n=2). The blue shaded areas in plots c) and d) represent the integrated area under the curve
calculated using a trapezoid approximation available in Origin 8.5 (Origin Lab Corp.,
Northampton, MA) [168].
c. Inclined plane
As pointed out in the introduction, a variety of methods can be used to study mucoadhesion
and in Table 7.1 a classification of methods is given based on the physical phenomena involved.
From a practical point of view it is useful to distinguish between mechanistic methods and
functionality (or performance) test methods; the first ones (the most common are rheological
and spectroscopic methods) give information on the events that occur at the mucoadhesive joint
in order to prove the interaction mechanisms, whereas the second ones are aimed at evaluating
the actual mucoadhesive properties/performance of formulations. In turn, they can be divided
into mechanical tests (the most common are tensile testing and rotational cylinder) intended to
measure the force needed to detach the formulation from the substrate and dynamic tests
(among which flow through or flow retention methods) intended to mimic the physiological
clearance mechanisms and to follow the fate of the formulation/loaded drug (retention on or
removal from the mucosal substrate). Mechanical and dynamic methods are believed to
provide information on the overall performance of the formulation as a delivery system.
The inclined plane method [169, 170] can be classified as a special dynamic test that measures
mucoadhesiveness as a function of the retention of the mucoadhesive material in contact with
a mucosal substrate (mucin film or mucosal tissue). It has been devised to test liquid or
semisolid formulations endowed with intrinsic flowing properties at test temperature. It is not
applicable to solid formulations or very thick gels.
Description of the apparatus
The inclined plane apparatus basically consists of a plexiglas support whose angle of
inclination with respect to the horizontal can be varied between 30° and 60°, thermostated at
37°C and placed above an electronic microbalance interfaced with a personal computer. An
illustrated picture of the apparatus, including details of the plexiglass support (which is
composed of a thermostated plate and an adapted substrate holder) is given in Figure 7.3.
Figure 7.3 Illustration of the inclined plane apparatus
The substrate holder (hosting two parallel channels) may be coated with a thin mucin film
(prepared by casting) or covered with mucosal tissue. The surface area coated is normally 28
cm2. The whole apparatus is placed in a transparent box allowing constant temperature to be
maintained and avoiding disturbances during the measurements. An overall picture of the
assembled apparatus is given in Figure 7.4.
Figure 7.4 Overall picture of the assembled apparatus
Description of the operational procedure for measuring mucoadhesive properties
The substrate holder is coated with the mucin film and equilibrated. Porcine gastric mucin is
normally used as biological substrate. Mucin films are prepared directly on the Plexiglas holder
in the horizontal position, by pouring a measured volume of 8% w/w mucin dispersion in water
then drying at 45°C for 45 min. A weighed amount of the formulation is placed on top of the
substrate holder, still held horizontal and until equilibrated. The support plate is then inclined
(at a given angle) and the amount of formulation dropped on the microbalance is recorded as a
function of time. Blank measurements are performed in the absence of the mucin film on a
weighed amount of sample using the same experimental conditions employed in the presence
of mucin. The amount of formulation dropped down the inclined plate is recorded by means of
suitable software as a function of time until a plateau is reached. The amount adhering to the
inclined plate is calculated as the difference between the amount of formulation loaded and the
amount dropped down from the balance (non-adherent) and expressed as a percentage (%
adhered). An example is given in Figure 7.5.
Figure 7.5 Plots of the amount of sample dropped (non- adherent) on the balance as a function
of time.
A normalized mucoadhesion parameter is calculated as follows: (% adhered mucin-% adhered
blank)/% adhered blank and is equal to 56%.This parameter allows the mucoadhesive
properties of a given formulation to be measured independently of the consistency of the
sample, since the blank measurement allows for normalization [170]..
Validation of the method
The inclination angle, quantity of mucin, length and width of the channels engraved on the
sample holder, sample weight influence test results and their reliability and must be optimized
to manage sample and testing variabilities. Recently these parameters have been the object of
a validation exercise aimed at 1) evaluating the capability of the method to discriminate
between different prototypes of a formulation intended for marketing and 2) assessing the
precision and reproducibility of the method as well as the robustness with respect to operational
parameters. This exercise could lead to the proposal of the method as a routine control method
for the quality of the product.
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Applications
The method has been profitably used to test the mucoadhesive properties of polymeric
solutions, liquid or gel formulations (mouthwashes, vaginal washings, eye drops, buccal
sprays, nasal washings, nasal sprays) [170] and even melted suppositories. The method has also
been employed to test mucoadhesive systems characterized by in situ gelling properties, like
swallowable gels intended for esophageal lining, or in situ gelling solutions used in diagnostic
colonoscopy, since it enables to evaluate the contribution of gelation time to mucoadhesive
performance [171].
d. Tensile testing
A texture analyzer can be used for the quantification of the tensile strength i.e. the force
required to remove the formulation from a mucosal surface, which can be used as a measure of
the mucoadhesive strength. In a generalized setup, the formulation is fixed on a probe which is
subsequently lowered into a mucus sample. After incubation that ensures full contact between
the formulation and the mucus, the mucoadhesive strength is measured as the force of
detachment. Formulations such as tablets [171], films, [172, 173] hydrogels, [174] and fibers [73, 82]
can be studied using this technique.
8. Cellular methods
Use of mucosal tissue of animal origin in mucoadhesion studies presents certain drawbacks,
such as limited availability, time-consuming tissue preparation, small surface area, or
significant variability of the obtained results [175]. In vitro study of mucoadhesion on cell
cultures is an example of alternative method of measurements, based on the interactions
between mucin and material of interest. Mucus-secreting HT29-MTX cell line is derived from
human colon adenocarcinoma and often used as a model for human intestinal adsorption or
buccal tissue in the oral cavity. Mucus secretion is depending on the culture period and usually
reaches maximum thickness after ca. 3 weeks of cell growth [176, 177]. Figure 8 presents the
HT29-MTX cells 1 and 14 days after passaging, respectively.
Figure 8.1 Morphology of the HT29-MTX cells 1 (a) and 14 days (b) after passaging.
There are several publications reporting use of cellular methods in mucoadhesion
measurements. Jintapattanakit et al. assessed the mucoadhesion of trimethyl chitosan and
PEGylated chitosan using HT29-MTX-E12 monolayers [178]. Fluorescently labeled polymers
were incubated with cells for 2 hours. Later on the cells were lysed and the uptake of polymers
was determined as the amount of fluorescence per unit weight of cellular protein. The obtained
results were similar when compared to mucin particle method. Chen et al. evaluated the
mucoadhesion of probiotic alginate microcapsules by counting Lactobacillus reuteri strain
released from the capsules adhering to the HT29-MTX after 1 hour of incubation. [179] In
another study, mucoadhesion of fluorescently labeled, non-coated and polymer-coated
liposomes was measured after 2 hour of incubation with HT29-MTX cell monolayer [180]. The
amount of liposomes adhering to the mucus was determined by measuring the fluorescence
intensity both directly on the cell monolayer and indirectly from the supernatant solution after
incubation.
9. Methods for characterising mucus permeability
One of the primary functional roles of mucins is to provide a barrier to bacteria while at the
same time allowing the passage of smaller components such as nutrients or gasses depending
on location. As a result the permeability of mucus and factors that can affect it are of great
interest. The permeability of mucus depends on the pore size of the network and the size of the
objects trying to pass through it. There have been essentially two types of approach used to
assess permeability, either measuring the diffusion of particles through mucus from different
sources or measurement of the pores directly, or indeed inferring it from the mucin structure.
There have been a number of studies undertaken using the first approach and involving the
tracking of particles of different sizes to determine pore size [24, 181-183]. The advantage of using
particles of a well-defined size is that the diffusion coefficient can be used to calculate the
microviscosity of the mucus sample (Stokes viscosity). For example, a study on human
cervicovaginal mucus using multiple particle tracking, revealed that the average pore size 340
+/- 70 nm and that the range was approximately 50–1800 nm [183]. For smaller particles,
fluorescence recovery after photobleaching (FRAP) has been used to determine diffusion
coefficients in mucus [24]. Using this method it was proposed that human cervical mucus had a
pore size of 100nm. This approach has also been extended to include gastric and intestinal
mucus, MUC5AC and MUC2 respectively. In this case the diffusion of 500 nm latex beads
was determined as a function of mucin concentration. The results showed that lowering pH
caused both mucins to gel and the addition of a polyphenol (epigallocatechin gallate) to porcine
gastric mucin caused a similar effect. A combination of FRAP and particle tracking has been
used to show that soluble dietary fiber can decrease the permeability of porcine intestinal
mucus [184]. Another approach that has been used is the use of optical tweezers to probe the
microrheology and particularly, the rigidity of the mucus scaffold in a noninvasive way on the
micrometer scale. [185] These approaches are in marked contrast to others who have tried to
estimate intestinal mucus permeability based on structural parameters [186]. This would indicate
a pore size of about 1 micron for intestinal MUC2 mucus. Such a size is significantly larger
than that measured by AFM in reconstituted MUC2 mucin that suggested a distribution of pore
sizes from 20 to 200 nm [25].
In addition to the pore size, the charge on mucus is a key factor in determining permeability.
The net negative charge carried by the mucins means that any positively charged particles or
polymers tend to be mucoadhesive. This has led to the widespread use of cationic biopolymers
such as chitosan for their mucoadhesive properties. In the small intestine, it has been shown
that 500 nm latex beads can diffuse through intestinal mucus when bile salts adsorbed to the
surface while they were unable to do so in the absence of bile. [26] In the same article the authors
were able to show that E. coli were unable to diffuse through the same mucus regardless of the
presence of bile. This suggested that a zeta potential of at least -20 mV was required for
permeability of these particles.
10. Application specific requirement
a. Gastrointestinal drug delivery
Oral delivery is the most commonly used and compliant drug administration way. MMoreover,
the all gastrointestinal tract (GI) is characterized by a highly absorptive surface which plays a
role both for local and systemic effects. An important disadvantage of this administration route
is however represented by the harsh conditions of the stomach which pose challenging goals
for the development of carriers for the delivery of poorly stable drugs such as antibiotic and
proteins and which goes towards the production of always more innovative and complex micro-
and nanoformulations. In this context, the mucus layer underlying the all GI tract, with its
variable in thickness and composition, represents the major protective barrier against foreign
particulate (e.g., bacteria but also micro-and nanoformulations). Nevertheless, this location
represents also an important anchoring site for mucoadhesive drugs formulations which avoids
their rapid clearance and improves their residence time in all the GI.
Several diseases affect all GI including accessories organs such as liver, pancreas and bladder.
Gastrointestinal diseases cover acute, recurrent and chronic diseases including inflammatory
bowel disease (IBD) and functional dyspepsia. Diseases of the upper part of the
gastrointestinal tract are often associated with the hostile presence of Helicobacter pylori,
the spiral-shaped Gram-negative bacteria which infect about half of the world population and
establish life-lasting bacteria-host relationship [187]. Because of the lack of symptoms in ~
60% of the infected people, its presence as a commensal or pathogenic bacteria is still
controversial [188]. However, in a relevant percentage of the cases, the perpetuation of the
inflammation of the gastric mucosa produces tissue damage that turns into more severe
pathologies such as gastric and duodenal ulcer, adenocarcinoma of the distal stomach or
MALT-lymphoma [189].
b. Advances in the therapy of Helicobacter pylori
The first-line therapy for the management of H.pylori infection, based on the concomitant
assumption of a proton-pump-inhibitor and a combination of two antibiotics (i.e. triple
therapy), is facing failure in ~ 20-30 % of the cases. This daunting efficacy is due to the
alarming increase of the antibiotic resistance in association with low patients compliance and
different disease’s status, high bacterial load and polymorphism between strains and poor drug
stability in the acidic environment [190, 191]. Improving drug stability, gastroretention at pH 1.2
and release at H. pylori surviving condition (pH 6-7) and site-specific targeting on H. pylori
surface are therefore the major outlook for new tailored and effective eradication therapy.
Along with the preparation of dosage forms whose prolonged residence time in the stomach is
due to their ability to float in the gastric fluid as the consequence of their low density[192], or
to unfold and expand as a result of their swelling properties [193, 194], great attempts have focused
on the formulations of polymeric micro-or nanoparticles with enhanced mucoadhesion ability
[195]. Several research groups have demonstrated proof-of-principle of the superior
antimicrobial activity of mucoadhesive micro- or nanoformulations both in vitro and in vivo
with respect to the plain drug [196-198].
Besides the large portfolio of synthetic polymers such as poly-acrylic acid (PAA) and
poly(lactic-co-glycol acid) (PLGA) and derivatives with proven mucoadhesive properties,
proteins, and polysaccharides, used singularly or together like building blocks of drug delivery
systems, also represent optimal materials. Among their advantages, include their
biodegradability, biosafety, ubiquity, nutritional value but also amenability to being chemically
manipulated [199]. In this regard, nanoparticles comprising gelatin [200] or gliadin (gluten-derived
proteins) have been developed for the release of amoxicillin [198], clarithromycin-omeprazole
[201] or clarithromycin-amoxicillin-omeprazole [202] for the treatment of H. pylori. While
alginate, heparin or chitosan are the first choices for the formulation of mucoadhesive
polysaccharide-based micro-and nanoformulations. The following section aims to review some
strategies adopted to improve the performance of mucoadhesive polymer-based micro-and
nanoformulations for gastric drug delivery.
Micro- and nanoformulation with improved gastroretention
Among mucoadhesive polysaccharides, chitosan, the semi-synthetic cationic
aminopolysaccharide derived by partial deacetylation of chitin, remains the most adopted
mucoadhesive biopolymer for the preparation of matrix-type or core-shell micro- and
nanosystems for the delivery of low-molecular-weight drugs such as antibiotics. But chitosan
is also a unique building block of galenic formulations due to its adjuvant properties and
antimicrobial activity toward pathogenic bacteria like H. pylori [203, 204]. Chitosan-based micro-
or nanoparticles can be prepared by ionotropic gelation with tripolyphosphate (TPP)[205],
covalent crosslinking and emulsification techniques [206]. The high solubility of chitosan at low
pH [207] and the high porosity of chitosan-microspheres, however, restrict its applications in
controlled release devices in the gastric compartment. Manipulating the crosslinking properties
[208] or the solubility of chitosan [209] represents, therefore, a strategy to overcome this limitation.
Exposing chitosan microsphere to reacetylation with acetic anhydride can modulate the release
of amoxicillin or metronidazole with respect the un-reacetylated formulation but can decrease
the encapsulation efficiency of metronidazole and also the antimicrobial activity if the exposure
time is too high [209]. Also, chemical crosslinking of chitosan microsphere with glutaraldehyde
[210] or with genipin [211], the low cytotoxic agent derived from hydrolysis of geniposide, can
prevent their rapid dissolution in simulated gastric fluid. Nevertheless, this procedure can
adversely influence the mucoadhesive properties of the microsphere if the crosslinking is
superior to optimal time [211]. Zhu et al. [212] solved the inconsistency between mucoadhesives
and controlled release by encapsulating a model drug into Eudragit® cores into chitosan/gelatin
microsphere only slightly crosslinked with TPP. In this study, the authors evaluated the effect
of type and density of crosslinking regard swelling properties, mucin adsorption on the surface
and in situ retention [212]. To protect chitosan-glutamic acid nanoparticles from rapid dissolution
at low gastric pH, Chang et al. [213] proposed an original approach. They included the
nanoparticles in a pH-sensitive gel comprising alginate-Ca2+ -gelatin which would adhere first
to the gastric mucosa, would shrink at pH 1.2 and protect the nanoparticle from rapid
dissolution, swell up to 50% at pH 4.5, and then collapse at pH 7 allowing 80% release
amoxicillin-nanoparticles. Beside chitosan, improved mucoadhesive properties can be
achieved using other polymer mixtures such as dextran derivatives (e.g., dextran sulfate) and
cellulose acetate [214], cholestyramine and cellulose acetate butyrate [215] or ethylcellulose and
carbopol-934P [216].
pH sensitive formulations
Due to its almost unique property among the biopolymers of bearing positive charges along its
chain, chitosan is often used in combination with other mucoadhesive negatively charged
polymers such as alginate (Arora et al 2011) or heparin [217, 218] to form polyelectrolyte
complexes. Because of the formation of polyelectrolyte complexes is often enthalpically
driven, (i.e., they are formed mainly by electrostatic interactions or hydrogen bonding), they
are more promising as stimuli-responsive materials [219]. Beside the fact that heparin has shown
to accelerate gastric ulcer healing, chitosan-heparin nanocomplex for the delivery of berberine,
a natural isoquinoline used in traditional Eastern medicine to treat gastro-enteritis, showed a
pH-dependent drug release which was up to 19% of the initial amount at pH 1.2, ~ 10% at pH
6 and ~ 50% at pH 7 due to collapse of the complex [218]. Chitosan-gold nanoparticles of size
below 50 nm were used to stabilize the surface of negatively charged liposomes comprising L-
α-phosphatidylcholine and 1,2-dioleoyl-sn-glycero-3-phosphate and prevent rapid liposome
aggregation and fusion [220]. Thus, the coated liposomes were able to release only 10% of
doxycycline pH 1.2 and a release up to 90% at pH 7.4 within 24 h and to fuse with the H. pylori
only at pH 7.4. Moreover, only the coated doxycycline-loaded liposomes were able to inhibit
the bacterial growth completely respect to the plain drug or the empty coated liposomes [220].
Site-specific drug targeting
Formulations of higher complexity comprise a functionalization of the surface which allows
specific interaction directly with H. pylori surface. With this purpose, Umamaheshwari et al.
[221] anchored on the surface of polyvinyl alcohol beads for the release of acetohydroxamic acid
a lipid bilayer of phosphatidylethanolamine (PE) with the aim of plug-and-seal specific
receptor on H. pylori surface. Besides their ability to inhibit the bacterial growth completely
and to be more stable than normal liposomes, they also showed to prevent the adhesion of H.
pylori to a cell monolayer and gastric tissue section [221]. The concept of plug-and-seal as an
approach to prevent bacterial infection is the topic of intense research of discovery of new
potential inhibitors (e.g., polysaccharide) and their usage as anti-adhesive preparation [222].
Due to the presence of adhesines on H. pylori surface able to recognize fucose-bearing antigens
on the epithelial/mucosal surface, fucose has been introduced in nanoformulation as targeting
moiety. Ramteke et al. used a carbodiimide method to conjugate covalently fucose to chitosan
[223]. This conjugate was used to prepare chitosan-glutamic acid nanoparticles for the
concomitant delivery of amoxicillin, clarithromycin and omeprazole which were able to
eradicate H. pylori from Swiss albino mice respect the unconjugated chitosan-glutamate
nanoparticles or plain drugs [223].
Lin et al. [197] combined the fucose-conjugated chitosan and genipin-crosslinking technology
to formulate a chitosan-heparin nanocomplex for the delivery of amoxicillin. Such a
formulation was obviously more effective in eradicating H. pylori from infected mice than
plain amoxicillin due to the most efficient interaction with bacterial receptor recognizing
fucose and also to reduce the H. pylori-associated gastric inflammation as concluded by
histological inspection [197].
More recently, a site-specific chitosan/TPP nanoparticle loaded with amoxicillin was produced
by conjugating chitosan with the ureidododecanoid acid, introducing, therefore, a moiety
recognized by the urease-transporter protein present on H. pylori surface [224]. The ureido-
modified nanoparticles were superior in inhibiting the bacterial growth respect plain
amoxicillin and unmodified chitosan/TPP ones. Moreover, such inhibition of the growth was
reduced by the addition of competitive substrate urea suggesting that the antibacterial activity
is due to a direct delivery of amoxicillin on the bacterial surface as evidenced by flow cytometry
analysis, CLSM imaging and OD measurements of bacterial growth [224].
c. In the oral cavity
The oral cavity includes different structures, most important being the lips, the cheeks, the
palate, the floor of the mouth and the tongue. The inner surface of the oral cavity is protected
by a mucous membrane. The secretion of saliva moisturizes the mucus membrane and form
the acquired enamel pellicle at the teeth and is by such very important in order to have a good
oral health [225]. Saliva is constantly produced from three major glands and is composed of
inorganic ions such as phosphate and calcium as well as organic constituents such as proteins,
carbohydrates and lipids. The microflora of the oral cavity is rich and more than 700 different
bacteria species can be found here [226]. The pH of a normal healthy mouth is around 6.5-7.5
[227].
The oral cavity can be used for both local drug delivery for treating different infections of the
oral mucosa and diseases connected to the teeth such as dental caries and periodontitis in
addition to systemic drug delivery via the buccal route.
The greatest challenge when aiming for drug delivery to the oral cavity is the secretion of saliva
which could be as high as up to 7 ml/min [228]. Saliva will efficiently flush any foreign
substances, also drugs, away. Also the gingival crevicular fluid (GCV) dilutes and flush away
substances placed in the periodontal pockets [229]. A mucoadhesive formulation has therefore
been proposed in order to prolong the residence time in the oral cavity. However, the mucus
layer of the oral cavity has a turnover rate of 12-24 hours [227]. This implies that the residence
time in the oral cavity can never be longer than this period of time. In addition, eating, drinking,
swallowing and chewing lower this period of time even further. Many new formulations have
lately been approved for treating periodontitis [230, 231]. The success of these formulations is due
to the use of mucoadhesive polymers enabling the formulation to stay as a reservoir in the
periodontal pockets for an extended period of time. However, the periodontal pockets can
perhaps be seen as an easier target than the oral mucosa; when the formulation is placed in the
pocket the environmental challenge is more predictable.
Different studies have revealed positively charged materials such as chitosan and positively
charged lipids to exert the highest mucoadhesive/bioadhesive properties in the oral cavity [232].
However, toxicity studies have shown that positively charged formulations seem to be more
toxic than their negative counterparts [233]. This complicates the picture since the formulations
with the highest degree of mucoadhesion also seem to give the highest toxicity.
A formulation, especially a nano- or micro formulation, placed in the oral cavity should also
be non-reactive towards saliva. Saliva is composed of globular proteins that can react with
the formulation. A study by Nguyen et al. showed that positively charged liposomes reacted
strongly with saliva. Also some of the negatively charged liposome reacted dependent on the
type of negatively charged lipid used [234]. However, when the liposomes were coated with
the biopolymer pectin, the interaction disappeared [235].
d. Colorectal drug delivery
The colorectal mucosa can be regarded as an optimal site for drug delivery, following oral or
rectal (e.g. suppositories, enemas etc.) administration. For instance, the colon mucosa contains
less digestive enzymes and therefore harbors reduced proteolytic activity than the mucosa of
the stomach or small intestine [236]. Thus, especially small peptides or proteins can be absorbed
in higher concentrations due to less degradation. Furthermore, colonic bacteria can be exploited
for the metabolism of prodrugs into effective metabolites [237].
These characteristics rendered the colorectal mucosa an important target for systemic drug
delivery. Furthermore, local administration of various drugs poses an important basis for the
treatment of various colorectal diseases such as infectious colitis, inflammatory bowel diseases
(IBD) or colorectal cancer. In this concern, it is challenging to optimize the bioavailability of
drugs with a maximum concentration at the absorbing/inflamed site for a prolonged time
together with minimal systemic side effects. Micro-and nanoformulations can be designed
either to increase the stability of drugs, to optimize the ratio between the loaded amount and
the loading volume, and to perform a passive or active delivery in the colorectal mucosa [238].
Charged biocompatible polymers (e.g polysaccharides) are able to interact with both healthy
and inflamed mucosa by virtue of their numerous charges, high molecular weight and chain
flexibility. In addition, some of them are characterized by pH-dependent properties (e.g
solubility), which render them optimal materials for the generation of micro-and
nanoformulations with mucoadhesive properties. This further enables a prolonged contact with
the mucosa and favors cellular uptake. Additionally, pH sensitivity protects the drug from the
acidic environment of the stomach and allows its release in lower GI regions [239].
Thus, mucoadhesive strategies have been exploited to improve systemic or local drug
administration in various ways. In the subsequent sections, we will discuss challenges and
strategies for colorectal targeting of mucoadhesive formulations and possible medical
indications.
Micro- and nanoformulations for colorectal delivery
Regarding the design of micro-and nanoformulation for colorectal application, large attention
has been posed to the use of polysaccharides due to numerous advantages namely i) their
susceptibility to degradation by glycosidases produced by the intestinal microflora, which
avoids their accumulation and favor drug release, ii) their ability to interact with the mucosa,
which favors prolonged contact with the absorption site, and in special cases iii) to function as
absorption enhancer or as promoter of wound healing [240].
Almost three decades ago, the ability of chitosan to promote drug absorption through the
intestinal epithelium and also other mucosas such as the nasal one was observed in models of
cell monolayers [241]. Since that, chitosan has been intensively used to generate challenging
formulations for the oral delivery drugs, e.g.insulin and others, in form of TPP-crosslinked
nanoparticles [242] alone or entrapped into a liposome structure [243], in combination with
alginate [244, 245], gum arabic [246], hyaluronic acid [247], lecithin [248] among many others.
Chitosan-based formulations can be tailored to specific purposes addressing for instance pH-
sensitivity by using a multi-ion crosslinking strategy based on TPP, SO42- and Mg2+ as recently
reported by Lin et al.,[249] or adding selective interaction with globet cells by chemically
modifying N-trimethyl chitosan chloride with a CSK targeting peptide [250]. Other authors use
chitosan and albumin to coat pH-sensitive insulin-loaded alginate/dextran sulfate nanoparticles
and investigated the delivery of insulin in presence or absence of inhibitors of permeability
[251]. Mucoadhesive formulations have not been proposed only for incorporation and delivery
of drugs for already established treatment (e.g insulin, steroids, IBD therapeutics [252]) as will
be discussed in the following section, but also for new therapeutic strategies such as delivery
of antisense RNA sequences (e.g siRNA technology)[253].
Mucoadhesive formulations for the treatment of colorectal inflammation and cancer
As previously discussed, mucoadhesive formulations have been evaluated in order to optimize
the local treatment of colorectal diseases. Currently available studies were mainly aiming at an
improved treatment of infectious colitis, inflammatory bowel diseases (IBD) such as Crohn’s
disease (CD) and ulcerative colitis (UC) and colorectal cancer (CRC).
Regarding infectious colitis, mucoadhesive formulations have been developed for the treatment
of Clostridium difficile infection (CDI). Clostridium difficile is a toxin-producing, gram-
positive bacterium that causes mild to severe colitis, frequently following previous treatment
with antibiotics. Symptoms range from asymptomatic carriage to severe disease with toxic
megacolon and standard treatment includes antibiotics such as vancomycin or metronidazole.
As infection reoccurs in about 10 to 40 percent of cases following initially successful therapy,
there is a huge demand for improved therapeutics. In order to increase colonic delivery of
vancomycin for the treatment of CDI, Bigucci et al. created vancomycin-containing
chitosan/pectin polyelectrolyte complexes [254]. These complexes show pH-dependent swelling
and drug release together with colonic mucoadhesion, which suggest superior drug delivery in
comparison to standard formulations. However, in vivo data supporting this concept are
missing so far.
In addition to infectious colitis, IBD also pose an interesting target for mucoadhesive drug
formulations. Both CD and UC result in a chronic relapsing inflammation of the
gastrointestinal tract that leads to severe complaints including diarrhea, abdominal pain, fever
and rectal bleeding in affected patients. Whereas UC is restricted to the large intestine, CD can
affect every part of the gastrointestinal tract including the large intestine. Treatment of IBD
includes various immunomodulatory approaches including salicylates, steroids,
immunosuppressives and biologicals such as anti-TNF therapeutics depending on the severity
of disease activity. Especially mild active disease is frequently treated with locally
administrated drugs such as salicylates and steroids as oral formulations, enemas or
suppositories. Especially oral drug delivery harbours the challenge of selective targeting of the
colorectal region in patients with Crohn’s colitis or ulcerative colitis. In this regard,
mucoadhesive strategies have been evaluated to improve colorectal drug delivery for IBD
treatment. Similar to colorectal drug targeting for systemic therapy, mucoadhesive
formulations containing chitosan and/or alginate particles have been exploited to deliver
standard IBD therapeutics such as 5-aminosalicylic acid [255] or prednisolone to the large
intestine [256, 257]. Interestingly, negatively charged liposomes show an improved drug delivery
in comparison to the free drug solution in experimental models of colitis, possibly due to an
increased adhesion of negatively charged liposomes to the inflamed mucosa. Again, most of
these data have been generated either in vitro or in vivo with preclinical models of intestinal
inflammation. Thus, a proof for a transfer of these strategies for the treatment of human
diseases is still missing.
e. Vaginal drug delivery
The vaginal tract has a relatively large surface area of 60 cm2 and a rich blood supply. The pH
of the vaginal tract is controlled by the bacteria Lactobacillus converting glycogen and
carbohydrates to lactic acid. The pH varies between 4 and 5 depending on the menstrual cycle
[258]. There are no secreting glands in the vagina and the amount of fluid is therefore sparse i.e.
around 6g [259]. Only small amount of additional liquid can be held without starting to leak out.
The vaginal fluid consists of inorganic and organic salts, mucin, proteins, carbohydrates, urea
and fatty acids. The vaginal fluid acts as a protecting barrier and consists of different
antimicrobial substances [260]. The surface of the vaginal tract is covered by a mucous
membrane. The mucin-layer consists of two different types of mucins; cell-associated mucin
and secreted mucin forming the outer layer [261]. The secreted mucin has a rapid turnover and
can trap foreign particles which will then be efficiently cleared away.
The vaginal tract can in principle be used for both systemic and local delivery of drugs, where
local drug delivery for combating for instance fungal, bacterial or viral infections has been the
interest of many studies.
There are many challenges related to achieving local drug delivery to the vaginal tract. The
formulation must be able withstand changes in the pH, release the drug in the small amount of
fluid present and also be able to penetrate the mucus layer before cleared away by the self-
cleaning action of vagina. In addition the formulation must not leak out of the vagina [261].
A mucoadhesive formulation will have the possibility of enhancing the time the formulation
stays in the vagina, however; often the formulation also need to penetrate the mucus layer in
order to achieve the desired effect. This could be complicated if the formulation stick too well
to the mucus layer. In addition, mucoadhesive particles may change the protecting properties
of the mucin-layer, letting both the drug and pathogens permeate the mucus barrier [262]. The
size of the particle seems to be important in order to be able to penetrate the mucus-layer.
Nanoparticles have therefore been proposed to be a promising formulation in order to achieve
local vaginal drug delivery [263]. A new approach for obtaining local vaginal drug delivery is
muco-resistant nanoparticles such as polyethylene glycol (PEG) coated particles [264]. These
particles can diffuse faster through the mucus-layer than mucoadhesive particles. The size of
the particles should be between 200-500 nm.
f. Nasal delivery
Since the pioneering studies on chitosan as a nasal penetration enhancer [265], the nasal route
has become an attractive option for transmucosal drug delivery, especially for protein/peptide
drugs. The nasal mucosa consists of epithelial cells underlined with rich vascularity that
provides direct entry of the drug into systemic circulation via passive diffusion and eventual
rapid onset of the pharmacological effect. The area available for drug absorption is relatively
large but still limited and not easily available. Similarly to the intestinal mucosa, nasal mucosa
is monostratified and characterized by the presence of tight junctions and by an abundant
mucus secretion. Approximately 1.5–2.0 litres of mucus are secreted daily by goblet cells and
serous glands within the nasal cavity, known to contain ca. 1% of proteins, including several
proteases[266]. Moreover, mucociliary clearance is a local defence mechanism with regard to
respiratory airways that tends to remove foreign bodies (namely bacteria) including
formulations from the mucosal site.
Due to the above anatomical and physiological constraints, administration of drugs with the
aim of systemic absorption inevitably requires the use of absorption promoters, typically
chemical penetration enhancers, but also of enzyme inhibitors, to escape peptidase action and
the use of mucoadhesive formulations to increase the duration and intimacy of contact with the
nasal mucosa. Finally, a prerequisite for nasally applied formulations is that it does not interfere
with normal nasal functioning. Since nasal mucosa is prone to be damaged by penetration
enhancers, which would impair its functions, special attention should be given to the
cytotoxicity of absorption promoters and the reversibility of their effect on the nasal membrane
should be ascertained.
Besides the vulnerability and the above limitations, the nasal route can be easily managed with
an appropriate mucoadhesive formulation for the administration of poorly absorbable
peptide/protein drugs[267] or by avoiding hepatic first-pass effect. The use of chitosan and
chitosan derivatives, well-known multifunctional polymers, certainly has represented a valid
strategy to overcome such limitations. [268, 269] The mucoadhesion properties of chitosan can be
exploited also in nasal administration of vaccines.[270] Due to the rapid entry to blood
circulation, the nasal route is also promising in the management of crisis situations and intense
acute pain, such as heart attack, hypoglycaemia, seizure, severe nausea and vomiting, or
breakthrough cancer pain.
Finally, nasal mucosa is also the target for locally applied, locally acting products intended for
the treatment of various upper respiratory syndromes such as flu-like symptoms (common cold)
and allergic rhinitis. These pathological conditions are characterised by an abundant mucus
production accompanied by headache and discomfort. Those symptoms might be caused by
viral/bacterial infections that are common pathologies affecting both adults and, more
frequently, children of school age. They might also be caused by acute and chronic reactions
to allergens.
Pharmacological treatment requires oral administration of anti-inflammatory drugs (aspirin,
paracetamol, NSAIDs) and antibiotics as well as local treatment, through sprays or aerosol,
with corticosteroids and antihistamines, which is likely to produce side effects such as mucosal
dryness and secondary fungal infections. Given that mucus overproduction is one of the most
fastidious symptoms, likely to be severe in children, a valuable approach could be to exploit
the well-known interaction between chitosan and mucins to obtain a mucolytic effect, thus
counteracting the mucus excess. The supposed mechanism of action is the physical interaction
between the negatively charged mucin macromolecules and the positively charged side groups
of chitosan. The approach has led to the development of a liquid nasal spray, having low
viscosity to ensure sprayability, intended to reduce or eliminate the excess of mucous liquid
production in rhino-faryngeal diseases (Figure 10.1).
Figure 10.1 Nasal spray
The commercial formulation, developed as a medical device and named Captomucil ® contains
a specially devised chitosan grade sourced from fungi having an average MW of 15000 Da and
a deacetylation degree of 70%, soluble at neutral pH (6-7) and lacking any irritancy towards
nasal mucosa (Patent App. N. MI2014A000825) and likely to produce a mucolytic effect even
at very low concentrations. To assess the functionality of the medical device, a rheological
approach was used, based on two different techniques [158, 271] to measure the interaction
between chitosan and mucin. Both techniques imply the use of highly-purified mucin, sourced
either from the submascillary cavity of cows or from the stomach of pigs. Two sets of
formulations were tested, that differed for the salt contents, since it is known that tonicity has
an effect on mucus rheology and on nasal mucociliary clearance [272]. In the first sets of
experiment, performed according Rossi S. et al.[158], an ipotonic Captomucil® formulation (i.e.,
without salt addition, with chitosan concentration ranging between 0.15-0.16 w/v), was
examined for its capability of reducing the viscosity of the submascillary bovine mucin solution
in the concentration range 0.5-6% w/w of mucin. The liquid formulation was mixed with mucin
solution at different concentrations (see Figure 10.2) in a volumetric ratio mimicking the
physiological one. Blank samples (mucin or formulation) were also prepared by diluting with
distilled water appropriate volumes of either mucin dispersion (mucin blank) or liquid
formulation (formulation blank).
Viscometric measurements were effected at 37°C on each and every set of samples (mucin
blank, formulation blank and mucin-formulation mixture) with a rotational rheometer. The
rheological interaction between mucin and chitosan was quantified by means of the rheological
synergism parameter ΔȠ (mPa.s), calculated with equation 3. 
ΔȠ= Ƞ mix - (Ƞ f + Ƞ muc ) Eq. 3
Where: Ƞmix=viscosity of the formulation and mucin mixture, Ƞf=viscosity of formulation
blank and Ƞmuc=viscosity of mucin blank. The results (Figure 10.2) showed positive rheological
synergism values at very low mucin concentration (0.5-% w/w) and low shear rates, whereas
at the highest mucin concentration (4-6% w/w) definite negative rheological synergism values
were recorded. Since the synergism values observed at low values (0.5-2% w/v) and at low
shear rates were affected by a high standard deviation, it was suggested that the method were
not sensitive enough at very low concentrations
Figure 10.2 Rheological synergism as a function of shear rate evaluated for five formulation-
mucin mixtures (mean values +/- sd; n=3)
By contrast, the definite negative synergism values observed at high concentrations (4-6% w/v)
indicated that, in those conditions, chitosan produces the maximum interaction with mucin
macromolecules. In other words, a massive precipitation of mucus should occur when in
presence of a very viscous mucus [273]. To deal with the limited sensitivity of the method at low
concentrations, in the second sets of experiments performed according to [271], three
Captpmucil® formulations having different contents in chitosan and sodium chloride (chitosan
concentration was 0.25, 0.45 and 0.16% w/v, NaCl concentration was 2.2, 2.2 and 0.40 w/v%,
respectively) were examined for dynamic viscosity using a falling sphere microviscometer.
Using this method it is possible to work at very low shear rate with precision and probe
differences in rheological behavior with a very high sensitivity. The deviation of the viscosity
of the mixture mucin/formulation from the sum of the viscosity of mucin solution plus the
viscosity of the formulation represents the rheological synergism that may be either positive or
negative depending on the sign of the deviation. The method allowed to explore
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mucin/formulation ratio much lower than the other method ranging between 0.1 to 1.0 The
results obtained for the 3 formulation tested are given in Figure 10.3.
Figure 10.3 Relative deviation (in %) from the additive line (i.e., of no interaction) of the
relative viscosity (ηrel) of chitosan-based Captomucil® formulations (as in label) in the
presence of pig gastric mucin as a function of mucin/formulation mass ratio f (37 °C).
A negative deviation is observed within the whole range of mucin/captomucil ratios tested and
the maximum negative deviation, meaning the maximum interaction and mucus precipitation
thereof, occurs in the whole range of mucin/formulation ratio for the mixture 1c (green
symbols) having the lower Captomucil® concentration and with the lower salt concentration
(slightly hypertonic formulation) whereas higher concentrations of Captomucil® and salt in 1a
and 1b (black and red symbols) (hypertonic formulation) caused a weaker interaction
specifically not in the whole range of ratios examined.
These results allowed to choose the best concentration of chitosan and salts for the final
formulation. Moreover, the results obtained demonstrate that the rheological approaches,
appropriately used according to physiological conditions; can be profitably used to measure
the precipitation capacity of mucolytic formulations.
11. Conclusion
In summary, throughout this review, we present an updated overview of the recent progress on
the experimental methods and applications in mucoadhesion research. As illustrated with
reference to specific cases, the method of choice to examine the mucoadhesive properties of a
given biomaterial (namely a medical device or pharmaceutical formulation) can vary widely.
A sounder understanding of the phenomena at play at the molecular level, that influence the
interactions of mucin and mucus with a large diversity of materials is likely to contribute to the
development of innovative applications on a more rational basis. Novel methods currently
under development and that have not been addressed in this review include the use of in vitro
cell culture or biomicrofluidics approaches.
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